Roundup: MedTech Europe welcomes European Health Data Space, AI detects interval breast cancers, and more briefs

Also, NHSE tech director Harjeet Dhalival to join Palantir.
By Tammy Lovell
05:39 AM

Credit: CardMedic

MedTech Europe welcomes launch of European Health Data Space  

The European Commission this week launched the European Health Data Space (EHDS), which will allow citizens to access their health data in any EU member state.

MedTech Europe CEO Serge Bernasconi, said: “To be successful, the proposed EHDS legislation needs to address the barriers to data sharing, advance investment in infrastructure, and foster the adoption of international interoperability standards. But first and foremost, it needs to lay the foundation for the building of trust in health data sharing amongst EU citizens.”

The proposal put forward by the European Commission will now be discussed by the Council and the European Parliament.

 

NHSE tech director Harjeet Dhalival to join Palantir

Former NHS England deputy director of data services Harjeet Dhalival is reported to be joining US software firm Palantir.

The news comes shortly after it was revealed that NHS’s former head of artificial intelligence (AI) Indra Joshi was joining the company, raising concerns about conflicts of interest. Palantir is competing for the £240 million NHS federated data platform (FDP) contract.

A Palantir spokesperson, said: “Palantir hires the best and brightest people from public and private sector organisations around the world. We are delighted that Harjeet is joining Palantir’s UK team, which we are aiming to grow by 250 this year.”

 

Study finds AI algorithm detects interval breast cancers

A study, published in the European Journal of Radiology, found that AI can correctly detect interval breast cancers in prior screening mammograms, including in some cases with no discernible suspicious signs.

The AI, developed by Berlin-based deep tech firm Vara, assessed 2,396 screening mammograms from women at the Mammography Reference Centre North in Germany, who were later diagnosed with an interval cancer.

In the cohort, 374 of the interval cancers were considered ‘false negative’ and 468 ‘minimal signs’. When the algorithm was set at an operating level of 99% specificity, it could detect and localise 27,5% (103) of the ‘false negative’ and 12,2% (57) of ‘minimal sign’ cancers.

 

Diaverum launches holiday dialysis booking platform

Renal care service provider Diaverum has launched a booking engine for holiday dialysis.  

The d.HOLIDAY booking platform allows users to apply search filters, select payment options in advance and have real-time visibility of treatment availability across Diaverum’s global network of clinics.

Michaela Blomstrand, director of patient experience and community affairs, Diaverum, said “Travel has already for some time evolved into a digital-led industry, and will continue to lean on digital innovation as it seeks to find agile ways of recouping its losses from the pandemic. Our strategy for d.HOLIDAY and our booking platform has been developed in line with this prediction”.

Want to get more stories like this one? Get daily news updates from Healthcare IT News.
Your subscription has been saved.
Something went wrong. Please try again.